149 related articles for article (PubMed ID: 37794100)
1. Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study.
Fattizzo B; Gurnari C; Cassanello G; Bortolotti M; Awada H; Giammarco S; Consonni D; Sica S; Gandhi S; Trikha R; Large J; Salter S; Maciejewski JP; Barcellini W; Kulasekararaj AG
Leukemia; 2023 Dec; 37(12):2479-2485. PubMed ID: 37794100
[TBL] [Abstract][Full Text] [Related]
2. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
Peffault de Latour R; Kulasekararaj A; Iacobelli S; Terwel SR; Cook R; Griffin M; Halkes CJM; Recher C; Barraco F; Forcade E; Vallejo JC; Drexler B; Mear JB; Smith AE; Angelucci E; Raymakers RAP; de Groot MR; Daguindau E; Nur E; Barcellini W; Russell NH; Terriou L; Iori AP; La Rocca U; Sureda A; Sánchez-Ortega I; Xicoy B; Jarque I; Cavenagh J; Sicre de Fontbrune F; Marotta S; Munir T; Tjon JML; Tavitian S; Praire A; Clement L; Rabian F; Marano L; Hill A; Palmisani E; Muus P; Cacace F; Frieri C; van Lint MT; Passweg JR; Marsh JCW; Socié G; Mufti GJ; Dufour C; Risitano AM;
N Engl J Med; 2022 Jan; 386(1):11-23. PubMed ID: 34986284
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin/Cyclosporine A in Immunosuppressive Therapy-naïve Patients with Aplastic Anemia in Japan.
Imada K; Obara N; Iida H; Imajo K; Maeda T; Usuki K; Fanghong Z; Hombo Y; Tajima T; Kumagai A; Matsuda A; Nakao S
Intern Med; 2021 Apr; 60(8):1159-1168. PubMed ID: 33229810
[TBL] [Abstract][Full Text] [Related]
4. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS
N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296
[TBL] [Abstract][Full Text] [Related]
5. A systematic review and meta-analysis of the safety and efficacy of anti-thymocyte globulin combined with eltrombopag in the treatment of severe aplastic anemia.
Zhang J; Wu Y; Liu J; Han S; Chen L; Wang H; Peng Y
Ann Palliat Med; 2021 May; 10(5):5549-5560. PubMed ID: 34107711
[TBL] [Abstract][Full Text] [Related]
6. [The efficacy of eltrombopag plus cyclosporine A in patients with transfusion-dependent non-severe aplastic anemia: a retrospective study from single center].
Chen Y; Zha Q; Huang F; Qiao C; Wang Y; Wang R; Li JY; Shen WY
Zhonghua Nei Ke Za Zhi; 2022 Apr; 61(4):409-411. PubMed ID: 35340188
[TBL] [Abstract][Full Text] [Related]
7. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia.
Lengline E; Drenou B; Peterlin P; Tournilhac O; Abraham J; Berceanu A; Dupriez B; Guillerm G; Raffoux E; de Fontbrune FS; Ades L; Balsat M; Chaoui D; Coppo P; Corm S; Leblanc T; Maillard N; Terriou L; Socié G; de Latour RP
Haematologica; 2018 Feb; 103(2):212-220. PubMed ID: 29170252
[TBL] [Abstract][Full Text] [Related]
8. Pilot study using tacrolimus rather than cyclosporine plus antithymocyte globulin as an immunosuppressive therapy regimen option for severe aplastic anemia in adults.
Zhu X; Guan J; Xu J; Wei J; Jiang L; Yin J; Zhao L; Zhang Y
Blood Cells Mol Dis; 2014 Sep; 53(3):157-60. PubMed ID: 24931461
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of 95 children with moderate aplastic anemia treated with horse antithymocyte globulin and cyclosporine.
Nishikawa E; Yagasaki H; Hama A; Yabe H; Ohara A; Kosaka Y; Kudo K; Kobayashi R; Ohga S; Morimoto A; Watanabe KI; Yoshida N; Muramatsu H; Takahashi Y; Kojima S
Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27808465
[TBL] [Abstract][Full Text] [Related]
10. Eltrombopag, oral immunosuppressant and androgen combination therapy in twelve patients with refractory severe aplastic anemia.
Gao Q; Zhang L; Zhao X; Zhu Y; Peng G; Li Y; Li Y; Li J; Song L; Ye L; Fan H; Zhou K; Yang W; Yang Y; Jing L; Zhang F
Hematology; 2020 Dec; 25(1):341-347. PubMed ID: 32915111
[No Abstract] [Full Text] [Related]
11. Eltrombopag in children with severe aplastic anemia.
Lesmana H; Jacobs T; Boals M; Gray N; Lewis S; Ding J; Kang G; Hale M; Weiss M; Reiss U; Wang W; Wlodarski M
Pediatr Blood Cancer; 2021 Aug; 68(8):e29066. PubMed ID: 33855784
[TBL] [Abstract][Full Text] [Related]
12. Eltrombopag added to immunosuppression for children with treatment-naïve severe aplastic anaemia.
Groarke EM; Patel BA; Gutierrez-Rodrigues F; Rios O; Lotter J; Baldoni D; St Pierre A; Shalhoub R; Wu CO; Townsley DM; Young NS
Br J Haematol; 2021 Feb; 192(3):605-614. PubMed ID: 33410523
[TBL] [Abstract][Full Text] [Related]
13. Eltrombopag for the treatment of aplastic anemia: current perspectives.
Lum SH; Grainger JD
Drug Des Devel Ther; 2016; 10():2833-2843. PubMed ID: 27695288
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up study of porcine anti-human thymocyte immunoglobulin therapy combined with cyclosporine for severe aplastic anemia.
Chen M; Liu C; Zhuang J; Zou N; Xu Y; Zhang W; Li J; Duan M; Zhu T; Cai H; Cao X; Wang S; Zhou D; Han B
Eur J Haematol; 2016 Mar; 96(3):291-6. PubMed ID: 25996247
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children.
Jie M; Fu L; Li S; He Y; Yao J; Cheng X; Zhang L; Zheng J; Zhang R; Wu R
Pediatr Hematol Oncol; 2021 Oct; 38(7):647-657. PubMed ID: 33798022
[TBL] [Abstract][Full Text] [Related]
16. Activity of eltrombopag in severe aplastic anemia.
Scheinberg P
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):450-456. PubMed ID: 30504345
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series.
Martynova A; Chiu V; Mert M; Hermel D; Weitz IC
Ann Hematol; 2021 Apr; 100(4):933-939. PubMed ID: 33420879
[TBL] [Abstract][Full Text] [Related]
18. Plain language summary of RACE study results: addition of eltrombopag to standard treatment of severe aplastic anemia.
de Latour RP; Kulasekararaj A; Iacobelli S; Griffin M; Halkes CJ; Dufour C; Risitano AM
Immunotherapy; 2024 Feb; 16(3):135-142. PubMed ID: 38088156
[TBL] [Abstract][Full Text] [Related]
19. Eltrombopag as frontline treatment of aplastic anaemia in routine practice: implications on cost and efficacy.
Hwang YY; Chan TSY; Chan FHY; Lau CWP; Luk YY; Lau GWN; Chan KP; Leung KH; Kho B; Lau JSM; Lau CK; Mak V; Yip SF; Lin SY; Sim JPY; Kwong YL
Ann Hematol; 2022 Jun; 101(6):1163-1172. PubMed ID: 35412083
[TBL] [Abstract][Full Text] [Related]
20. Real-world experience of treatment with thrombopoietin receptor agonists in anti-thymocyte globulin-naïve patients with aplastic anemia: an observational retrospective analysis in a single institution.
Iino M; Jinguji A; Sato T; Nakadate A
Hematology; 2022 Dec; 27(1):360-366. PubMed ID: 35306963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
